Established and Future Promising Fertility Preservation Options in Adolescence and Adults by Yazdekhasti, Hossein & Rajabi, Zahra
REVIEW ARTICLE
Established and Future Promising Fertility Preservation Options for Adolescent and Adult 
Cancer Patients: a Review of Current Advances
Hossein Yazdekhasti1, Zahra Rajabi2
1Cell biology department, University of Virginia, USA
2Department of Biomedical Engineering, University of Virginia, USA
Corresponding Author: Hossein Yazdkhasti, E‑mail: hosein.yazdekhasti@yahoo.com. Phone: hosein.yazdekhasti@yahoo.com.
Internal Medicine and Medical Investigation Journal
E-ISSN: 2474-7750
Homepage: www.imminv.com
ABSTRACT
Background: Over the past decades, improved diagnostic and prognostic procedures have 
resulted in an increased number of cancer survivors; with this, the demand for fertility preservation 
options has risen dramatically. Cancer patients who are interested in fertility preservation have 
several options that can be pursued based on age, risk of gonadal involvement, time available, 
and type of cancer, each with different advantages and disadvantages. Methods: Relevant 
papers were identified using a computerized literature search on recent papers in PubMed and 
MEDLINE. Results: Of all possible options, embryo cryopreservation for women and semen 
freezing for men are the most common; however, gonadal tissue cryopreservation and oocyte 
cryopreservation are other promising options that can be considered if a partner is not available. 
Both women and men with cancer benefit from adequate consultation regarding possible fertility 
preservation options. Conclusion: Providing patients and their families with immediate and 
accurate information helps ensure that the best fertility preservation decisions are made.
INTRODUCTION
Based on World Health Organization (WHO) reports and 
those from other organizations, infertility is a common condi‑
tion. Worldwide, 72.4 million women are estimated to be in‑
fertile; of these, an estimated 40.5 million are currently seek‑
ing medical treatment for infertility (1). In 2005, a national 
survey of family growth in the United States reported that, 
between 1995 and 2002, there was a 20% increase in Ameri‑
can couples experiencing infertility (2). Another report found 
a rise in infertility from 42% to 48.5% from 1990 to 2010, 
which might be related to delayed parenthood and childbear‑
ing in the third decade of life, and which consequently re‑
sulted in a decrease in ovum and sperm quality in couples. 
Statistical reports predict an even lower future fertility rate 
and a higher infertility prevalence with the advent of some 
complex diseases, which decrease fertility potential in both 
women and men (3). Cancer is one of these complex diseases, 
and infertility is one of the most serious consequences of ra‑
dio/cytotoxic treatment, which can affect the quality of life of 
cancer survivors. Some chemotherapeutic agents, particular‑
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ly alkylating agents such as busulphan; ionizing radiotherapy 
to the abdomen or pelvic region; and surgical procedures can 
destroy the gonads and lead to infertility (4‑7).
Thus, new treatments based on novel technologies need 
to be developed. One of the most promising is assisted repro‑
ductive technology (ART), which involves embryo produc‑
tion in vitro and then transfer of the embryos to the uterus. 
In addition, stem cell treatments can help couples have their 
own genetic babies and eliminate possible ethical consider‑
ations that might be raised from sperm, oocyte, or embryo 
donation (8‑16).
Sterility after aggressive cancer treatment, especially in 
adolescence, is one of the most complicated and psycholog‑
ically difficult issues that families face. Some studies have 
shown that cancer patients have a reduced fertility potential 
even before starting treatment (17‑20). For this kind of in‑
fertility, some reasons have been proposed: primary or sec‑
ondary hormonal imbalance; anatomic changes (retrograde 
ejaculation); damage to supporting cells or germinal stem 
cells; reduction of sperm DNA integrity, numbers, and mo‑
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tility; and a decrease in pituitary gonadotropin levels, all of 
which can negatively affect fertility (11,12,21,22).
During certain cancer treatments, most germ cells in the 
gonads will be destroyed, resulting in the patient being per‑
manently sterile. Therefore, the employment of fertility pres‑
ervation methods is indispensable. These methods should 
also be affordable. Each year, many types of research are con‑
ducted to develop appropriate methods for fertility cryopres‑
ervation. Those who may also benefit from fertility preserva‑
tion methods are patients who have non‑oncologic diseases; 
patients with chromosomal abnormalities (e.g., Turner’s 
syndrome); patients with autoimmune disorders; patients 
with severe or recurrent endometriosis;  patients treated with 
gonadotoxic agents that can cause premature ovarian failure; 
and couples who postpone parenthood into their fourth or 
fifth decades of life (23).
It was reported that, by January 2012, approximately 13.7 
million cancer survivors were living in the United States, with 
the number projected to approach 18 million by 2022. Because 
of this tremendous increase in the number of cancer survivors, 
developing new fertility preservation methods is a critical issue 
(24). In this article, we review the available and experimental 
fertility preservation methods for adolescent and adult cancer 
patients and discuss their advantages and disadvantages (Ta‑
ble 1). These options are a combination of recent developments 
in ART, cryotechnology, and innovative cell culture systems.
AVAILABLE AND EXPERIMENTAL FERTILITY 
PRESERVATION OPTIONS FOR MALES
I was estimated that one in every 640 young adults in the USA 
would be a survivor of childhood cancer  (25), indicating that 
there is high demand for fertility preservation in adolescence. 
Unfortunately, prepubescent males have limited options and 
pose a particular challenge for fertility preservation due to 
their inability to produce semen for cryopreservation. There 
are some ways to produce semen samples from prepubescent 
males, but samples are frequently of poor quality (26,27). 
 Although prepubescent testes have spermatogonial stem cells 
(SSCs), for fertility preservation purposes mature spermato‑
zoa are indispensable. Research on the use of SSCs for the 
restoration of fertility in cancer survivors is ongoing. To date, 
these studies have led to the production of live offspring only 
in rodents. However, these significant achievements in ro‑
dents may possibly pave the way for the future use of SSCs 
for fertility preservation in routine ART procedures.
Another approach involves the cryopreservation of tes‑
ticular tissue before the onset of aggressive cancer treatment. 
Then, years later, once the patient is ready to have a family, 
the testis tissue is thawed and used in either auto‑transplan‑
tation of testicular tissue or in vitro maturation of SSCs until 
they can be used for intracytoplasmic sperm injection (ICSI) 
(10, 28, 29). Meanwhile, SSCs can be transplanted back into 
another host (xeno‑transplantation) to encourage spermato‑
genesis; however, before such methods can be used in clini‑
cal settings, many legal, ethical, and clinical concerns must 
be adequately addressed (30). Most crucially, there is a risk 
of reintroducing cancer cells with testicular tissue transplan‑
tation, with potentially fatal consequences.
For adult patients, semen cryopreservation is a standard, 
established, and successful technique after cancer diagnosis, 
and treatments can be started as soon as possible. Studies 
indicated that cryopreservation led to the deterioration of se‑
men quality by, on average, 31% in terms of motility, 37% in 
terms of morphology, and 36% in terms of mitochondrial ac‑
tivity (31). However, using ICSI and other ART procedures, 
these defects can be mitigated. For these reasons, it is highly 
recommended that 2‑3 ejaculates per patient be obtained, be‑
cause semen quality may be low.
Semen samples can be collected through masturbation. 
If there is a difficulty, alternative measures are penile vibra‑
tory stimulation, rectal electrostimulation under anesthetic, 
testicular sperm extraction from a biopsy, and collecting 
spermatozoa in urine samples (27,32). Cryopreservation of 
SSCs retrieved from mature testes is yet another option and 
is considered a promising future method. However, many 
additional studies are needed to investigate how SSCs can 
be used for fertility preservation purposes in routine ART 
clinical procedures.
Other methods exist, but these are still under investiga‑
tion and in clinical trials. Gonadal shielding during radia‑
tion therapy is one of these methods with established clinical 
applicability. Shielding can be used to reduce the dose of 
radiation delivered to the testicles (33). Testicular suppres‑
sion with gonadotropin‑releasing hormone (GnRH) analogs 
or antagonists is another method. Using hormonal therapies, 
testicular tissue can be protected from the harmful effects 
of chemotherapy or radiation. There is, however, a body of 
evidence showing the ineffectiveness of this approach (34).
Although fertility preservation methods are highly rec‑
ommended, they are not always offered to patients. Avoid‑
ing a delay in the onset of anti‑cancer therapy is the primary 
reason. Others include the belief that sperm banking is less 
efficient in adolescents; high costs; poor prognostic proce‑
dures; lack of adequate facilities; and the belief that cancer 
treatment can have profound infertility consequences (35).
AVAILABLE AND EXPERIMENTAL FERTILITY 
PRESERVATION OPTIONS FOR FEMALES
For prepubescent girls, several fertility preservation strat‑
egies might be helpful, although most methods are exper‑
imental and require further investigation and clinical trials 
before they can be used prior to aggressive cancer treatment. 
Of these methods, ovarian tissue cryopreservation is the most 
promising. Recent reports showed that ovarian tissue trans‑
plantation resulted in more than 90 live births (36). Although 
live births have been achieved by this method, ovarian tis‑
sue cryopreservation and thawing after cancer treatment and 
puberty is not yet an available option for the public. This 
approach is still considered experimental. Additional studies 
and approval by institutional review boards are required be‑
fore it can become a standard fertility preservation method 
in ART clinics (37).
Another experimental fertility preservation method that 
gives hope to female cancer patients is the isolation of fol‑
licles from cortical strips and ovarian biopsies (38). How‑
ever, progress and achievements in this particular approach 
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Table 1. Advantages and disadvantages of fertility preservation options (* = options that are experimental and not 
clinically available)
Sex Age Options Advantages and disadvantages
Males Adolescents Semen freezing, if applicable
Cryopreservation of SSCs*
Cryopreservation of testis tissue*
Radiation shielding of gonads
Poor quality
Expensive and requires further procedures; higher 
number of SSCs in adolescent boys than adults
Expensive and requires further procedures; risk of 
reintroduction of cancer cells; no available human
success rates
Not satisfying results; only possible with selected 
radiation fields and anatomy; expertise needed to ensure 
that shielding does not affect reproductive organs
Adults Semen freezing
Testicular sperm extraction
Cryopreservation of SSCs*
Cryopreservation of testis tissue*
Radiation shielding of gonads
Testicular suppression with 
gonadotropin‑releasing hormone (GnRH) 
analogs or astagonists 
The most applicable option; best results
Can be done after treatment; low rate of success required 
outpatient procedures
Expensive and requires further procedures; lower number 
of SSCs in adolescent boys than adults
Expensive and requires further procedures; risk of 
reintroduction of cancer cells; no available human 
success rates; requires outpatient procedures
Not satisfying results; only possible with selected 
radiation fieldss and anatomy; expertise needed to ensure 
shielding does not affect reproductive organs
Controversial; not satisfying results in clinical trials; 
no surgery needed; not expensive and easy to perform; 
needs more evidence to be applicable
Females Adolescents Ovarian tissue cryopreservation*
Isolation and cryopreservation of immature 
follicles*
Cryopreservation of ovarian stem cells*
Expertise required; expensive; risk of reintroduction of 
cancer cells; the only available approach for prepubescent 
girls; allows natural pregnancy after auto‑transplantation; 
fewer ethical dilemmas; no ovarian stimulation required; 
low success rate; not available in every clinical setting
Requires outpatient procedures; expensive; no live birth 
evidence in humans
Further evidence required; highly controversial; 
outpatient procedures needed
Adults Embryo cryopreservation
Mature oocyte cryopreservation
Immature oocyte cryopreservation*
Oophoropexy
GnRH analogs
Cryopreservation of ovarian stem cells*
Well‑established and most reliable option; high 
pregnancy rate; best option when sufficient time is 
available before cancer treatment; requires a male 
partner or sperm donation; requires ovarian stimulation; 
not applicable for women who have hormone‑sensitive 
cancers; requires outpatient surgical procedure
No ethical problems; no urgent need for sperm; applicable 
for single women; low pregnancy rate but acceptable 
fertilization rate; requires ovarian stimulation and delay in 
cancer treatment; not suitable for PCOS patients because of 
the high risk of OHSS; requires outpatient surgical procedure
No delay in cancer treatment; higher fertilization rate 
compared to the mature oocyte; IVM needed; no ovarian 
stimulation needed; not expensive; no needed for a 
partner or sperm donation
No satisfying results; can be performed in all ages; surgical 
procedures required; ovarian function can be preserved; no 
ethical problems; spontaneous pregnancy may not be possible
Controversial; not satisfying results in clinical trials; 
no surgery needed; not expensive and easy to perform; 
needs more evidence to be applicable; spontaneous 
pregnancy possible; ovarian function can be preserved
Further evidence required; highly controversial; 
outpatient procedures needed
GnRH: Gonadotropin-releasing hormone; IVM: In vitro maturation; OHSS: Ovarian hyperstimulation syndrome; PCOS: Polycystic ovary syndrome; 
SSC: Spermatogonial stem cell
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are mostly in rodents, and it seems unlikely that this method 
will be available soon in larger animals and humans. The 
possible strategy involves obtaining multiple ovarian biop‑
sies from young patients through either laparoscopy section 
or oophorectomy and then isolating follicles from ovarian 
tissue and cryopreservation. After cancer treatment, follicles 
will be returned to patients either by auto‑transplantation or 
in vitro maturation to produce a live birth by in vitro fertil‑
ization.
Treatment with ovarian stem cells is another novel fer‑
tility preservation approach. Considerable controversy ex‑
ists among reproductive scientists regarding the existence 
of ovarian stem cells in adolescents and adults. However, if 
present, ovarian stem cells could potentially be used in the 
future for fertility preservation purposes (8‑10,13,15).
Shielding ovaries is another fertility preservation meth‑
od, in which ovaries are protected from the side of effects 
of radiation by surgical transposition (39,40). However, 
since pelvic irradiation has a destructive effect on the uter‑
us, the probability of a natural pregnancy is significantly 
reduced (41), even if ovarian function is preserved.
Regarding possible fertility preservation methods in 
adult women, the most routine and applicable method is em‑
bryo preservation, if a partner is available. In the absence of 
a partner, oocyte freezing can be performed. Most of these 
methods are expensive, require surgery, and are not as reli‑
able as sperm cryopreservation in males. They are routine‑
ly applied based on a patient’s marital and economic status, 
age, time available, and risk of ovarian involvement (39,42).
At the 2012 American Society for Reproductive Medi‑
cine (ASRM) meeting, embryo preservation was defined 
as the only established method for fertility preservation in 
adult women. The safety and effectiveness of this method 
have been proven. Now, embryo preservation is a part of 
routine ART clinics for infertile women, enabling storage of 
supernumerary embryos. It can also be used for women with 
ovarian hyperstimulation syndrome or impaired endometri‑
al development, or for impractical embryo transfer (43,44). 
Recent reports have indicated that oocyte and embryo cryo‑
preservation result in similar pregnancy rates; therefore, the 
current revised ASRM and American Society of Clinical On‑
cology guidelines recommend oocyte freezing as an appli‑
cable and trusted method for patients for whom a partner is 
not available (37,45,46). Although embryo cryopreservation 
is the most established fertility preservation method, recent 
progress and clinical experiments indicate that the rate of 
pregnancy after oocyte freezing is increasing dramatically. 
In addition, the pregnancy rate after the transfer of frozen/
thawed embryos is even higher than fresh embryo transfer 
cycles (47).
Oocytes can be cryopreserved at either the mature or 
immature status. Single women and those who do not have 
access to a sperm donor can pursue this option. To avoid any 
delay in beginning cancer treatment, treatment can be start‑
ed as soon as possible. During the procedure, the immature 
oocyte is retrieved from the ovary through ovarian tissue 
cryobanking or oophorectomy (48). This method might have 
some advantages over mature oocyte freezing. Some studies 
showed that immature oocytes are less vulnerable to ultralow 
temperatures and to cryodamage, due to lack of metaphase 
spindle and lower cell volume, but the main obstacle is low 
pregnancy rate and low developmental capacity after fer‑
tilization of immature oocytes (49, 50). To our knowledge, 
there is no report of a live human birth after fertilization with 
cryopreserved oocytes and transfer of immature oocytes. 
Additional clinical and experimental studies are necessary 
before this can become a routine clinical procedure.
Owing to recent significant progress and achievements 
in humans, cryopreservation and transplantation of ovarian 
tissue is another promising fertility preservation method that 
has attracted the attention of reproductive and oncologic sci‑
entists (51,52). It has been proven that immature oocytes are 
more resistant to cryodamage within primordial follicles in 
ovarian tissue (53). However, the main obstacle to further 
advances is how to activate quiescent follicles after freezing 
and thawing procedures. Cryopreserved ovarian tissues can 
be used by three possible methods: auto‑transplantation, xe‑
no‑transplantation, and in vitro culture of immature follicles. 
In this context, auto-transplantation is the only clinically 
relevant strategy and has led to over 90 live births (54,55). 
Xeno‑transplantation has shown potential to be a promising 
method in humans and animals; however, it has raised many 
ethical and legal concerns that need to be fully addressed. 
Another, much more complicated, method is the in vitro cul‑
ture of immature follicles. In this method, primordial, prima‑
ry follicles or even pre‑ovulatory follicles are isolated from 
ovarian fragments and then cultured in the presence of other 
supplementations and conditions. Later, metaphase I oocytes 
are retrieved from mature follicles, and through a process 
called in vitro maturation, oocytes are matured (metaphase 
II) and fertilized by ICSI or in vitro fertilization. Many re‑
markable achievements have been made using this method, 
mostly in rodents and farm animals; however, to be a clin‑
ically acceptable method in humans, further studies and in‑
vestigations are required (56,57). Notably, transplantation of 
ovarian tissue risks the reintroduction of malignant cells to 
the patient’s body. Thus, before starting the process of trans‑
plantation, cancer cells must be absent from ovarian tissue 
fragments (58,59).
To minimize the deleterious effects of ionizing radiation 
on the ultrastructure and function of ovarian tissue, particu‑
larly in the cases of Hodgkin disease and abdominal surgery, 
oophoropexy, or ovarian transposition, is another method 
that is routinely used in clinics (60). Although this method 
is clinically relevant, the outcomes are not satisfying con‑
sidering how directly dependent the outcomes are on radia‑
tion dose, patient age, whether concomitant chemotherapy is 
used, and whether the ovaries are shielded (5,61).
There is one final fertility preservation method in which 
ovaries can be protected from chemotherapy‑induced dam‑
age (34). In this method, agonists of GnRH are administrated 
to patients before the onset of chemo/radiotherapy. These ag‑
onists increase the probability of spontaneous menstruation 
within 3‑8 months after the termination of chemotherapy. 
Even though this method is only in clinical trials, its clinical 
applicability is controversial (62‑64).
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CONCLUSION
Additional methods for fertility preservation exist. The clin‑
ical applicability of these methods depend on the results 
of ongoing clinical trials, further investigations, and oth‑
er validation measures. Some approaches, such as sphin‑
gosine‑1‑phosphate, AS101, and imatinib, have demon‑
strated protective effects on germ cells via suppression of 
apoptosis pathways in germ cells after the devastating con‑
sequences of radio/cytotoxic treatments. 
In conclusion, as the number of cancer survivors has in‑
creased dramatically over the past few decades, so too has 
the demand for fertility preservation. Most patients are now 
aware of the detrimental effects of cancer treatments, and 
they are seeking a variety of fertility preservation options. 
In addition, industrialization, the desire for increased socio‑
economic status, and the growing demand for employment 
are other reasons why people postpone childbearing and 
which have led to more requests for fertility preservation 
options. Both women and men with cancer benefit from ad‑
equate consultation regarding possible fertility preservation 
options. Providing them and their families with immediate 
and accurate information helps ensure that the best fertility 
preservation decisions are made.
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